MyotonicPipeline.com
Astellas Gene Therapies
Drug: AT466
Approach: AAV-antisense
Status: Preclinical.
Company website explaining AT466.
April 8, 2019 Press Release announcing collaboration with Nationwide Children's Hospital
Dec. 2021 Press Release announcing collaboration with Dyno for viral vector delivery technology.